摘要
目的评价替格瑞洛联合不同剂量替罗非班对经皮冠状动脉介入治疗(percutaneous coronary interven⁃tion,PCI)术后无复流的临床疗效。方法检索万方医学、CBM中国生物医学、知网医学、Cochrane Library、PubMed、Embase,检索自建库至2023年1月,替格瑞洛联合不同剂量替罗非班治疗PCI术后无复流的临床随机对照试验。3名研究者独立筛选收集、提取、评估相关数据。应用Review Manager 5.3软件进行Meta分析。结果本研究共纳入5个临床随机对照试验,561例患者。结果显示替格瑞洛联合半量替罗非班治疗与替格瑞洛联合全量替罗非班治疗比,可有效降低无复流发生率、减少主要心脏事件发生率、增加TIMI血流3级事件发生率并有效降低出血事件发生率,差异有统计学意义(OR=0.47、0.49、2.30、0.49,P<0.05)。结论替格瑞洛联合半量替罗非班治疗,可更好地降低PCI术后无复流发生率、出血事件发生率和主要心脏事件发生率,增加PCI术后TIMI血流3级发生率。
Objective To evaluate the clinical effect of ticagrelor combined with different doses of tirofiban on noreflow after percutaneous coronary intervention(PCI).Methods Retrieve Wanfang Medicine,CBM China Biomedical,CNKI Medicine,Cochrane Library,PubMed,Embase,and search for a clinical randomized controlled trial of tigrel combined with different doses of tirofiban in the treatment of non reflow after PCI from the establishment of the data⁃base to January 2023.Three researchers independently screened,collected,extracted,and evaluated relevant data.Ap⁃ply Review Manager 5.3 software for meta-analysis.Results This study included a total of 5 clinical randomized con⁃trolled trials with 561 patients.The results showed that the combination of tigrinolol with half dose tirofiban and tigri⁃nolol with full dose tirofiban significantly reduced the incidence of no reflow,decreased the incidence of major cardiac events,increased the incidence of TIMI grade 3 blood flow events,and effectively reduced the incidence of bleeding events,the difference was statistically significant(OR=0.47,0.49,2.30,0.49,P<0.05).Conclusion Ticagrelor com⁃bined with half-dose tirofiban can better reduce the incidence of no-reflow,bleeding events and major cardiac events after PCI,and increase the incidence of grade 3 TIMI blood flow after PCI.
作者
赵蒙
李丽
赵振宇
ZHAO Meng;LI Li;ZHAO Zhenyu(Linyi Central Hospital,Linyi,Shandong Province,276400 China)
出处
《系统医学》
2023年第12期31-36,共6页
Systems Medicine
基金
山东省医药卫生科技发展计划项目(202003070410)。
关键词
替格瑞洛
替罗非班
无复流
PCI术
META分析
Ticagrelor
Tirofiban
No-reflow
Percutaneous coronary intervention
Meta-analysis
